Biotie Buying VC-Backed Elbion
Biotie, a publicly-traded Finnish company, has agreed to acquire Elbion GmbH, a German drug company focused on neurology and immunology. No financial terms were disclosed. Elbion shareholders – including Burrill & Co., TVM Capital and AGF Private Equity – have agreed to buy approximately $4.2 million of new shares in Biotie as part of the deal, while Elbion will also receive around 46.8 million new Biotie shares. Elbion had raised around $62 million in VC funding.
27 October 2008•4 mins read
